The primary patent protecting Tresiba (insulin degludec) in the United States is set to expire in 2031 [1]. However, the situation surrounding Tresiba's patent exclusivity is complex, involving multiple patents and potential legal challenges.
When Does Tresiba's Patent Actually Expire?
While the main patent expires in 2031, Tresiba is protected by a portfolio of patents. The earliest the primary patent protection ends is 2031 [1]. Information on the precise expiry dates for all related patents and potential extensions is available through resources like DrugPatentWatch.com [2].
What Happens When Tresiba's Patent Expires?
Once the key patents expire, it opens the door for the potential development and approval of generic versions of Tresiba. This could lead to increased competition and potentially lower prices for patients [3].
Can Biosimilars Enter Before Patent Expiry?
Tresiba is a biologic drug, meaning that the generic equivalents are referred to as biosimilars. The pathway for biosimilar approval and market entry is distinct from that of small-molecule generics. The intricate patent landscape and regulatory approvals can influence when biosimilars might become available [4].
Who is Developing Tresiba?
Tresiba is a long-acting basal insulin developed by Novo Nordisk [1].
What is Tresiba Used For?
Tresiba is used to improve glycemic control in adults and children 1 year and older with diabetes mellitus [1]. It is a once-daily injection that helps manage blood sugar levels [1].
What are the Risks Associated with Tresiba?
Like all insulins, Tresiba carries risks, including hypoglycemia (low blood sugar), which is the most common side effect. Other potential side effects include allergic reactions, changes in potassium levels, heart failure, and lipodystrophy at the injection site [1].
How Does Tresiba Compare to Other Basal Insulins?
Tresiba is known for its ultra-long duration of action, offering flexibility in dosing time. It is often compared to other long-acting basal insulins like Lantus (insulin glargine) and Levemir (insulin detemir), with differences in pharmacokinetic profiles and potential impacts on glycemic control and hypoglycemia risk [5].
Where Can I Find More Information on Drug Patents?
Detailed patent information, including expiry dates and litigation related to various drugs like Tresiba, can be found on websites such as DrugPatentWatch.com [2].
**Sources:
1. Novo Nordisk. (n.d.). *Tresiba® (insulin degludec) Injection Prescribing Information.
2. DrugPatentWatch.com. (n.d.). Tresiba Patent Expiry. Retrieved from https://drugpatentwatch.com/
3. U.S. Food & Drug Administration. (n.d.). Generics.
4. U.S. Food & Drug Administration. (n.d.). Biosimilars.
5. Rosenstock, J., et al. (2013). Insulin degludec versus insulin glargine in type 1 diabetic patients: Interaction between basal insulin and mealtime bolus in basal-bolus therapy. Diabetes Care, 36(9), 2595-2601.